These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

829 related articles for article (PubMed ID: 30954510)

  • 21. [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
    Strojek K; Yoon KH; Hruba V; Elze M; Langkilde AM; Parikh S
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S16-26. PubMed ID: 23529567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
    Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
    Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    Ridderstråle M; Andersen KR; Zeller C; Kim G; Woerle HJ; Broedl UC;
    Lancet Diabetes Endocrinol; 2014 Sep; 2(9):691-700. PubMed ID: 24948511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.
    Yang W; Han P; Min KW; Wang B; Mansfield T; T'Joen C; Iqbal N; Johnsson E; Ptaszynska A
    J Diabetes; 2016 Nov; 8(6):796-808. PubMed ID: 26589253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
    Häring HU; Merker L; Seewaldt-Becker E; Weimer M; Meinicke T; Woerle HJ; Broedl UC;
    Diabetes Care; 2013 Nov; 36(11):3396-404. PubMed ID: 23963895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.
    Shigiyama F; Kumashiro N; Miyagi M; Ikehara K; Kanda E; Uchino H; Hirose T
    Cardiovasc Diabetol; 2017 Jul; 16(1):84. PubMed ID: 28683796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
    Rosenstock J; Jelaska A; Frappin G; Salsali A; Kim G; Woerle HJ; Broedl UC;
    Diabetes Care; 2014 Jul; 37(7):1815-23. PubMed ID: 24929430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
    Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
    Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study.
    Tang Y; Sun Q; Bai XY; Zhou YF; Zhou QL; Zhang M
    Nutr Diabetes; 2019 Nov; 9(1):32. PubMed ID: 31685792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride.
    Chirila C; Zheng Q; Davenport E; Kaschinski D; Pfarr E; Hach T; Palencia R
    Qual Life Res; 2016 May; 25(5):1199-207. PubMed ID: 26424170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
    Aronson R
    Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
    Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
    BMC Health Serv Res; 2015 Nov; 15():496. PubMed ID: 26541516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
    Nauck M; del Prato S; Meier JJ; Durán-García S; Rohwedder K; Elze M; Parikh SJ
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S6-15. PubMed ID: 23529570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial.
    Heo JH; Han KA; Hong JH; Seo HA; Hong EG; Yu JM; Jung HS; Cha BS
    Diabetes Metab J; 2024 Sep; 48(5):937-948. PubMed ID: 38310875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
    Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
    Ridderstråle M; Rosenstock J; Andersen KR; Woerle HJ; Salsali A;
    Diabetes Obes Metab; 2018 Dec; 20(12):2768-2777. PubMed ID: 29961998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
    Søfteland E; Meier JJ; Vangen B; Toorawa R; Maldonado-Lutomirsky M; Broedl UC
    Diabetes Care; 2017 Feb; 40(2):201-209. PubMed ID: 27913576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Bolinder J; Ljunggren Ö; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S
    Diabetes Obes Metab; 2014 Feb; 16(2):159-69. PubMed ID: 23906445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.
    Henry RR; Murray AV; Marmolejo MH; Hennicken D; Ptaszynska A; List JF
    Int J Clin Pract; 2012 May; 66(5):446-56. PubMed ID: 22413962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.